Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Autosomal Dominant Polycystic Kidney Disease
2023-505890-34-00Phase 4Authorised
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Empagliflozin (Jardiance) with Placebo (2 arms). Primary endpoint: Relative change in total kidney volume. Planned start Mar 2024; status: authorised.
02
Drugs
empagliflozin
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2023-505890-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505890-34-00.